Vivos Inc
Vivos Inc., a radiation oncology medical device company, develops brachytherapy devices for the treatment of non-resectable tumors in the United States. The company develops an yttrium-90 based precision radionuclide therapy device; RadioGel, which is an injectable particle-gel for Precision Radionuclide Therapy radiation treatment of cancerous tumors in people and animals; and IsoPet for the tre… Read more
Vivos Inc (RDGL) - Total Liabilities
Latest total liabilities as of September 2025: $112.69K USD
Based on the latest financial reports, Vivos Inc (RDGL) has total liabilities worth $112.69K USD as of September 2025.
Total liabilities represent everything the company owes to external parties, combining both current liabilities—like accounts payable, short-term debt, and accrued expenses—and non-current liabilities such as long-term debt, pension obligations, lease liabilities, and deferred tax liabilities.
Vivos Inc - Total Liabilities Trend (2014–2024)
This chart illustrates how Vivos Inc's total liabilities have evolved over time, based on quarterly financial data. Explore and compare other companies by total liabilities.
Vivos Inc Competitors by Total Liabilities
The table below lists competitors of Vivos Inc ranked by their total liabilities.
| Company | Country | Total Liabilities |
|---|---|---|
|
Ayen Enerji AS
IS:AYEN
|
Turkey | TL8.97 Billion |
|
Sena Development Public Company Limited
BK:SENA
|
Thailand | ฿24.25 Billion |
|
Rupa & Company Limited
NSE:RUPA
|
India | ₹4.97 Billion |
|
Gatekeeper Systems Inc
PINK:GKPRF
|
USA | $4.20 Million |
|
Digihost Technology Inc
NASDAQ:DGHI
|
USA | $12.34 Million |
|
Tubos Reunidos S.A
MC:TRG
|
Spain | €447.35 Million |
|
Valhi Inc
NYSE:VHI
|
USA | $1.31 Billion |
Liability Composition Analysis (2014–2024)
This chart breaks down Vivos Inc's total liabilities into key components over time: long-term debt, short-term debt, other current liabilities, and other non-current liabilities. Toggle between absolute values and percentage view to see how the composition has shifted.
Liquidity & Leverage Metrics
Key Metrics Explained
| Metric | Value | Description |
|---|---|---|
| Current Ratio | 20.37 | Measures ability to pay short-term obligations (Current Assets ÷ Current Liabilities) |
| Quick Ratio | N/A | More stringent measure of short-term liquidity ((Current Assets - Inventory) ÷ Current Liabilities) |
| Cash Ratio | N/A | Most conservative liquidity measure (Cash & Equivalents ÷ Current Liabilities) |
| Debt to Equity | 0.05 | Measures financial leverage (Total Liabilities ÷ Shareholder Equity) |
| Debt to Assets | 0.05 | Portion of assets financed with debt (Total Liabilities ÷ Total Assets) |
Liability Trends Comparison
This chart compares key liability metrics across different time periods, showing how Vivos Inc's debt structure has evolved. The comparison includes total liabilities, long-term debt, and current liabilities.
Annual Total Liabilities for Vivos Inc (2014–2024)
The table below shows the annual total liabilities of Vivos Inc from 2014 to 2024.
| Year | Total Liabilities | Change |
|---|---|---|
| 2024-12-31 | $86.21K | -64.81% |
| 2023-12-31 | $245.00K | +199.91% |
| 2022-12-31 | $81.69K | -51.06% |
| 2021-12-31 | $166.91K | -81.57% |
| 2020-12-31 | $905.50K | -40.57% |
| 2019-12-31 | $1.52 Million | +58.93% |
| 2018-12-31 | $958.66K | -77.59% |
| 2017-12-31 | $4.28 Million | -75.14% |
| 2016-12-31 | $17.21 Million | +72.61% |
| 2015-12-31 | $9.97 Million | -50.78% |
| 2014-12-31 | $20.25 Million | -- |